⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MDCX News
Medicus Pharma Ltd. Common Stock
Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome
globenewswire.com
MDCX
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
globenewswire.com
MDCX
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ:SDST)
accessnewswire.com
MDCX
SDST
VTIX
VVOS
YYGH
DVLT
CISO
LTRN
CAST
New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms
accessnewswire.com
MDCX
Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
globenewswire.com
MDCX
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
globenewswire.com
MDCX
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
globenewswire.com
MDCX
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)
accessnewswire.com
ACXP
DVLT
IGC
NRXP
SNYR
TRN
VTIX
VVOS
YYGH
MDCX
ATON
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
globenewswire.com
MDCX
Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update
accessnewswire.com
MDCX